Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes

Diabetes Care

Volumn 25, Issue 3, 2002, Pages 517-523

  Miyazaki, Yoshinori ^a   Matsuda, Masafumi ^a   DeFronzo, Ralph A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHOLESTEROL; THIAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CORRELATION ANALYSIS; DOSE RESPONSE; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; STATISTICAL SIGNIFICANCE; BLOOD; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC DIET; DIET RESTRICTION; DRUG EFFECT; ETHNIC GROUP; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SECRETION;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHNIC GROUPS; FASTING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0036517099     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.3.517     Document Type: Article

References (29)

1. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus; a randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:176-185, 1998
2. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW, and the Troglitazone Study Group: Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. J Clin Endocrinol Metab 83:3169-3176, 1998
3. Spiegelman BM: PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514, 1998
4. Hallakau S, Doare F, Foufelle F, Kergost M, Guerre-Millo, Berthault MF, Dugail I, Mortin J, Auwerx J, Farre P: Pioglitazone induces in vivo adipocyte differentiation in obese Zucker fa/fa rats. Diabetes 46:1393-1399, 1997
5. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD: Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137:4189-4195, 1996
6. Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RN, Meglasson MD: Pioglitazone increase insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant rhesus monkeys. Diabetes 43:204-211, 1994
7. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathsen A, Schneider R, The Pioglitazone 001 Study Group: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 23:1605-1611, 2000
8. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahanlai S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA: Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710-719, 2001
9. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470, 1999
10. Turner R, Holman R, Matthews D, Hockaday T, Peto J: Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism 28:1086-1096, 1979
11. Patel J, Anderson RJ, Rappaport EB: Rosiglitazone monotherapy improve glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes, Obesity and Metabolism 1:165-172, 1999
12. Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT, The Glipizide Gastrointestinal Therapeutic System Study Group: Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Diabetes Care 20:597-606, 1997
13. DeFronzo RA, Goodman AM, and The Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
14. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S: Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23:1660-1665, 2000
15. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Yajima N, Ikeda Y: Effects of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22:908-912, 1999
16. Inzucchi SE, Maggs D, Spollet GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867-872, 1998
17. Rossetti L, Giacarri A, DeFronzo RA: Glucose toxicity. Diabetes Care 13:610-630, 1990
18. Diamond MP, Thornton K, Connoly-Diamond M, Sherwin RS, DeFronzo RA: Reciprocal variation in insulin-mediated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance. J Soc Gynecol Invest 2:708-715, 1995
19. Frias JP, Yu JG, Kruszynska YT, Olefsky JM: Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care 23:64-69, 2000
20. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
21. Ferrannini E, Reichard GA, Bjorkman O, Wahren J, Pilo A, Olsson M, DeFronzo RA: The disposal of an oral glucose load in healthy subjects: a quantitative study. Diabetes 34:580-588, 1985
22. Kawamori R, Matsuhisa M, Kinoshita J: Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 41:35-43, 1998
23. DeFronzo RA, Ferrannini E, Simpson DC: Fasting hyperglycemia in non-insulin dependent diabetes mellitus: contribution of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38:387-395, 1989
24. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazer MA, Chatterjee VKK, O'Rahilly S: Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100:3149-3153, 1997
25. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Cusi K, Mandarino L, DeFronzo RA: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus (Abstract). Diabetes 49 (Suppl. 1):A229, 2000
26. Evans DI, Hoffmann RG, Kalkhoff RK, Kissebah AH: Relationship of body fat topography to insulin sensitivity and metabolic profiles in premenopausal women. Metabolism 33:68-76, 1984
27. Randle PJ, Garland PB, Hales CN, Newsholme EA: The glucose-fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-789, 1963
28. Boden G: Role of the fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10, 1997
29. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardham R, Freed MI: Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 43:278-284, 2000